Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...
Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results